Searchable abstracts of presentations at key conferences in endocrinology

ea0063oc6.4 | Obesity | ECE2019

Fat mass impact of sirolimus after clinical islet transplantation, a case control study

Jannin Arnaud , Espiard Stephanie , Hoth-Guechot Helene , Kerr-Conte Julie , Pattou Francois , Vantyghem Marie-Christine

Introduction: Sirolimus, a mTOR (mechanistic Target of Rapamycin) inhibitor, is well known for its impact on glucides and lipids metabolism. These effects vary according to factors such as dose and treatment duration, species, cell types and environmental factors. In vitro and in vivo, sirolimus inhibits adipogenesis by decreasing adipocytes number and size, as well as pre-adipocytes differentiation, leading to subcutaneous and visceral fat mass decrease in m...

ea0090p536 | Late-Breaking | ECE2023

Role of insulin therapy in weight gain: lessons from islet transplantation in type1 diabetes

Romain Bulois , Jannin Arnaud , Defrance Frederique , Mapihan Kristell Le , Mikael Chetboun , Julie Kerr-Conte , Francois Pattou , Vantyghem Marie-Christine

Background: Weight gain in type 1 diabetes (T1D) patients has become a clinical problem due to less strict diets and more stringent glycemic targets. Thus, the number of overweight T1D in the USA increased from 3.4% in 1988 to 22.7% in 2007. Hyperinsulinism is involved in the genesis of obesity but in T1D, the impact of insulin therapy in weight gain is not established. Islet transplantation, now reimbursed in France, makes it possible to interrupt insulin. The aim of this wor...

ea0063p808 | Thyroid 2 | ECE2019

Clinical presentation of hypothyroidism caused by TSH-receptor antibody

Jannin Arnaud , Peltier Lucas , D'Herbomez Michele , Defrance Frederique , Marcelli Sophie , Ben Hamou Adrien , Humbert Linda , Wemeau Jean-Louis , Vantyghem Marie-christine , Espiard Stephanie

Introduction: Anti-thyrotropin receptor antibodies (TSHR-Abs) stimulating the thyroid (TSAb) are responsible for GravesÂ’ disease. In some patients, the TSHR-Abs can block thyrotropin action (TBAb) and cause hypothyroidism, the switch between stimulating and blocking activity in GravesÂ’ disease being well. This reports aims to describe clinical presentation of patients affected directly by hypothyroidism.Material and methods: Retrospective clini...

ea0070ep12 | Adrenal and Cardiovascular Endocrinology | ECE2020

Altered bone mass and microarchitecture in catecholamine-secreting malignant paraganglioma

Jannin Arnaud , Beron Amandine , Vieillard Marie-Hélène , Vantyghem Marie-Christine , Chapurlat Roland , Do Cao Christine , Espiard Stephanie

Introduction: Pheochromocytoma and most abdominal paraganglioma (PPGL) can secrete catecholamines. In vitro and in vivo, catecholamines modulate bone remodeling by stimulating bone resorption. In patients with PPGL, four studies have previously demonstrated an increase of biological markers of bone resorption, a decreased of bone density and a higher prevalence of vertebral fractures. We report two patients with malignant abdominal secreting paraganglioma pre...

ea0092ps3-27-06 | Thyroid Cancer clinical 3 | ETA2023

Skeletal related events in differentiated thyroid carcinoma with bone metastasis: A bicentric study

Jannin Arnaud , Lamartina Livia , Djennaoui Mehdi , Chevalier Benjamin , Hadoux Julien , Moutarde Coralie , Lion Georges , Vantyghem Marie-Christine , Deschamps Frederic , Baudin Eric , Schlumberger Martin , Leboulleux Sophie , Do Cao Christine

Purpose: Bone metastases (BM) are frequent in differentiated thyroid cancer (DTC). These patients may present skeletal-related events (SRE), the leading cause of DTC-related morbidity. We aimed to evaluate the clinical features, treatment approaches, and outcomes including overall survival (OS) of DTC patients with BM complicated by SRE and their evolution over time.Methods: 178 consecutive DTC patients harbouring BM were enrolled in this retrospective s...

ea0081p140 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Benderradji Hamza , Elise Vernotte , Ares Gustave Soto , Jean Philippe Woillez , Romain Perbet , Melodie-Anne Karnoub , Benoit Soudan , Arnaud Jannin , Assaker Richard , Luc Buee , Prevot Vincent , Claude-Alain Maurage , Pascal Pigny , Marie-Christine Vantyghem , Emilie Merlen , Cortet Rudelli Christine

Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and patients: This single-center retrospective study included 21 patients who were newly diagno...